D-Ribose
A five-carbon sugar that forms the backbone of ATP and is the rate-limiting substrate for the de-novo synthesis of adenine nucleotides. Marketed for energy, heart failure and fibromyalgia recovery; genuine clinical benefit is limited and best supported in rare myoadenylate deaminase deficiency, with mainstream ergogenic claims largely unsupported.
01 Overview
D-ribose feeds the pentose-phosphate pathway and provides the sugar backbone of ATP, so supplementation is proposed to accelerate replenishment of adenine nucleotide pools depleted by ischaemia or intense exercise. The strongest rationale is in tissues where nucleotide resynthesis is genuinely rate-limiting.
Evidence in healthy athletes is weak: most controlled studies find no meaningful improvement in performance, and any benefit appears confined to specific pathological states such as myoadenylate deaminase deficiency and, more tentatively, symptomatic relief in heart failure or fibromyalgia. It is generally well tolerated but can lower blood glucose and cause GI upset at higher doses.
02 Mechanism
Supplies the ribose backbone for de-novo adenine-nucleotide (ATP) synthesis and feeds the pentose-phosphate pathway, potentially accelerating nucleotide pool recovery in energy-depleted tissue.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Supplement | 5–15 g/day | Oral | Common supplemental range, often split; doses to ~10-15 g/day in heart-failure studies. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Nucleotide replenishmentAccelerates ATP pool recovery in ischaemic/depleted tissue in experimental models. | Preclinical | ||
| Symptom relief in specific conditionsSmall studies suggest benefit in myoadenylate deaminase deficiency and, tentatively, heart failure and fibromyalgia. | modest | Observational | |
| Athletic performanceMost controlled trials in healthy athletes show no ergogenic benefit. | Disputed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HypoglycaemiaCan transiently lower blood glucose, especially on an empty stomach. | Mild | Dose-related | Clinical | |
| Gastrointestinal upsetNausea and diarrhoea with large single doses. | Mild | At high doses | Clinical |